FIELD: biotechnology; virology; medicine.
SUBSTANCE: oncolytic virus is presented that contains (1) a first expression cassette containing a first promoter and a first interfering RNA expression sequence; (2) target sequence; and (3) a second expression cassette. The first interfering RNA expression sequence is used to express the first interfering RNA that binds to the target sequence. The first interfering RNA expression sequence is under the control of the first promoter to express the first interfering RNA in the first cells. The target sequence is located in the 5' or 3' non-coding region of an essential gene required for oncolytic virus replication. The second expression cassette contains the second promoter and the expression sequence of the inhibitory component. The expression sequence of the inhibitory component is used to express the inhibitory components. Inhibitory components are used to inhibit the biosynthesis and/or bioactivity of enzymes involved in the biosynthesis of interfering RNA. The expression sequence of the inhibitory component is under the control of the second promoter in order to express the inhibitory components in the second cells, but not in the first cells. The first and second cells are different cell types, and the first cells are non-mammalian tumor cells and the second cells are mammalian tumor cells. The following are presented: a nucleic acid molecule for use as an oncolytic virus genome; a composition for producing an oncolytic virus; a method for producing an oncolytic virus; the use of an oncolytic virus for the preparation of a drug that selectively kills cells; a method of cell destruction; a drug to kill cells; a method of treating a disease in a subject; the use of an oncolytic virus to selectively kill cells.
EFFECT: oncolytic virus can selectively replicate in various cell types, and thus tumor cells can be selectively killed while normal cells remain intact.
33 cl, 7 dwg, 6 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
ONCOLYTIC HSV-VECTOR | 2014 |
|
RU2719190C2 |
ONCOLYTIC HERPES SIMPLEX VIRUSES TYPE 1 FOR TREATING BRAIN TUMOURS | 2021 |
|
RU2824514C1 |
CONSTRUCTION OF OBLIGATE VECTOR BASED ON ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) AND CONSTRUCTS FOR CANCER THERAPY | 2016 |
|
RU2751236C2 |
PHARMACEUTICAL COMPOSITIONS, KITS AND METHODS OF TREATING TUMORS | 2019 |
|
RU2810906C2 |
THERAPEUTIC COMPOSITIONS AND METHODS OF USING FOR TREATING CANCER | 2016 |
|
RU2720984C2 |
ADENOVIRUS CONTAINING ALBUMIN-BINDING SITE | 2015 |
|
RU2711371C2 |
DOUBLE-STRANDED RNA CAPABLE OF REDUCING EXPRESSION OF MUTANT ALLELE C.607G>A OF HUMAN GNAO1 GENE | 2022 |
|
RU2816137C1 |
GENETIC MAKE-UPS FOR ANTI-HIV THERAPY | 2010 |
|
RU2426788C1 |
TREATMENT OF TUMORS WITH A COMBINATION OF ONCOLYTIC ADENOVIRUS AND CDK4/6 INHIBITOR | 2019 |
|
RU2811278C2 |
IMPROVING GENETIC CONSTRUCTS FOR PROVIDING HIGH EFFICACY OF ANTI-HIV THERAPY | 2013 |
|
RU2533817C1 |
Authors
Dates
2023-05-02—Published
2020-05-28—Filed